logo
Share SHARE
FONT-SIZE Plus   Neg

Sanofi Says JCO Publishes Positive VELOUR Study Results Of Cancer Drug ZALTRAP

French drug giant Sanofi S.A. (SNY) on Monday said the detailed positive results from the pivotal Phase III VELOUR study evaluating ZALTRAP (aflibercept) Injection for Intravenous Infusion for patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology or JCO.

The company said the latest data supported the regulatory approval of ZALTRAP by the U.S. Food and Drug Administration on August 3 after a Priority Review.

ZALTRAP is a recombinant fusion protein that binds to Vascular Endothelial Growth Factor or VEGF- A, VEGF-B, and placental growth factor. Sanofi and Regeneron Pharmaceuticals, Inc. (REGN) share equally the global profits of ZALTRAP.

The Phase III VELOUR study was a multinational, randomized, double-blind trial comparing FOLFIRI in combination with either ZALTRAP or placebo in the treatment of patients with metastatic colorectal cancer previously treated with an oxaliplatin-containing regimen.

Sanofi noted that ZALTRAP in combination with the FOLFIRI chemotherapy regimen in the trial showed a statistically significant improvement in overall survival as the primary endpoint, while secondary endpoints included progression-free survival, the overall tumor response rate versus placebo plus FOLFIRI, and safety.

The VELOUR trial showed that in patients previously treated with an oxaliplatin-containing regimen, adding ZALTRAP to FOLFIRI significantly improved median survival from 12.06 months to 13.50 months, an 18 percent relative risk reduction.

The company also observed a significant improvement in progression-free survival from 4.67 months to 6.90 months, a 24 percent relative risk reduction. The overall response rate in the ZALTRAP plus FOLFIRI arm was 19.8 percent vs. 11.1 percent for FOLFIRI, the company noted.

The drug is approved in the U.S. with the US proper name ziv-aflibercept for use in combination with FOLFIRI for patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. ZALTRAP is under review at the European Medicines Agency and other regulatory agencies worldwide.

Debasish Roychowdhury, Senior Vice President and Head of Sanofi Oncology, said, "We want to express our appreciation to the authors and the editorial board of the JCO for publishing the results of the VELOUR trial. The scrutiny of the FDA review and peer review processes should provide physicians confidence in the results of VELOUR, as they make important decisions for their patients."

Sanofi shares closed Friday's regular trading session at $44.64, up $0.41 or 0.93 percent.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
PepsiCo Inc. (PEP) is bringing back Crystal Pepsi, the colorless soda launched in 1992, a move that the food and beverages giant expects will boost its slowing sales. The 1990s-era clear soda will go on sale in 20-ounce bottles for a limited time at major retailers starting July 7 in Canada and August... The U.S. Federal Communications Commission Wednesday said it has finished the first stage of a spectrum auction and has acquired $86.4 billion worth of wireless airwaves from television broadcasters in a reverse bid. The FCC will now will sell the TV spectrum to cellular service providers in a forward... Allegiant Air will start offering service from Newark Liberty International Airport, after the low-cost airlines received approval from the Federal Aviation Administration. Allegiant will begin offering flights in November between Newark and Cincinnati, Ohio; Savannah, Georgia; Asheville, North Carolina...
comments powered by Disqus
Follow RTT